|
UBE2D3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.43849426498855E-15 |
| Normal-vs-Stage2 |
4.55570026147711E-10 |
| Normal-vs-Stage3 |
4.32986979603811E-15 |
| Normal-vs-Stage4 |
1.63546953757532E-12 |
| Stage1-vs-Stage2 |
5.995000E-01 |
| Stage1-vs-Stage3 |
7.283600E-02 |
| Stage1-vs-Stage4 |
3.961500E-02 |
| Stage2-vs-Stage3 |
4.727400E-01 |
| Stage2-vs-Stage4 |
2.267200E-01 |
| Stage3-vs-Stage4 |
5.435600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
2.03919999999247E-05 |
| Normal-vs-Asian |
3.182498709009E-11 |
| Caucasian-vs-AfricanAmerican |
1.930760E-01 |
| Caucasian-vs-Asian |
6.303200E-01 |
| AfricanAmerican-vs-Asian |
3.751800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.22044604925031E-16 |
| Normal-vs-Female |
1.62503344114384E-12 |
| Male-vs-Female |
1.782170E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.97915034255902E-12 |
| Normal-vs-Age(41-60Yrs) |
4.44089209850063E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62492241884138E-12 |
| Normal-vs-Age(81-100Yrs) |
2.279200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.935600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.985600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.416600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.150000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.609400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.280200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.509700E-02 |
| Classical-VS-Follicular |
8.794000E-01 |
| Classical-VS-Other |
2.255800E-01 |
| Classical-VS-Normal |
1.62470037423645E-12 |
| Tall-VS-Follicular |
4.751700E-02 |
| Tall-VS-Other |
9.426000E-01 |
| Tall-VS-Normal |
4.40347758257076E-12 |
| Follicular-VS-Other |
3.658600E-01 |
| Follicular-VS-Normal |
1.50089995987202E-09 |
| Other-VS-Normal |
4.08790000000492E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.295763827462E-14 |
| Normal-vs-N1 |
1.77635683940025E-15 |
| N0-vs-N1 |
1.923850E-02 |
|
|
